|
|
|
|
|
by dablweb
1824 days ago
|
|
Your argument is sound. It is however, built on one glaring assumption: the people in charge of the publicly funded healthcare systems are primarily incentivized to find cheap and safe treatments for the illness. I think when you look at the selective medicare payments, the ventilator contracts, and the price of the 'recommended' patent-drugs like Remdisivir... it quickly becomes apparent that our public incentive structure is profoundly broken. |
|
You don't have to have recommended patent-drugs unless, of course, they are the best option. Sometimes the newer drugs really are better.